课题基金 / 基金详情

项目摘要

项目成果

LARISA Y POLUEKTOVA的其他基金

相似基金

相关文献

中文摘要
翻译
这个子项目是众多研究子项目之一
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Approximately 40 million are infected with HIV-1. Worldwide 33% of HIV patients have chronic hepatitis C virus (HCV) infection and 10% of the HIV-infected population also have chronic hepatitis B (HBV). Almost 90% of intravenous drug users have HIV/HCV co-infection. The significance of such a proposal relates to the absence of an adequate animal model of hepatitis B and C, and co-infection of HIV-1,2 and hepatitis viruses, which represent the real situation in humans. The combination of two infections is related to a significant medical complication in the HIV-1-infected population. HCV, HBV and HIV infections are human infections, which cannot be distinguished in rodents. Thus, only by reconstitution of a mouse with a human immune system where the mouse liver has human hepatocytes will create an adequate model to study human immune response to viral antigens, thereby providing an excellent tool for vaccine development. This unique rodent model allows generation of data that previously could be obtained only in virally infected patients, limiting the necessity of further human studies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
ANTI-VIRAL PEPTIDE NANOCOMPLEXES (APN) FOR TREATMENT OF HIV/HCV CO-INFECTION
ANTI-VIRAL PEPTIDE NANOCOMPLEXES (APN) FOR TREATMENT OF HIV/HCV CO-INFECTION
SUBTYPE C HIV VACCINE TESTING IN HUMANIZED MICE
  • 批准号:
    7719943
  • 项目类别:
  • 资助金额:
    $28.4万
  • 财政年份:
    2008
  • 负责人:
    LARISA Y POLUEKTOVA
  • 依托单位:
Humanized mice for Neuro AIDS
海外基金